The adenosine a2A-receptor antagonist istradefylline enhances the motor response of L-DOPA without worsening dyskinesia in MPTP-treated common marmosets

Journal of Pharmacological Sciences

Volumn 124, Issue 4, 2014, Pages 480-485

  Uchida, Shin Ichi ^a   Tashiro, Tomomi ^a   Kawai Uchida, Mika ^a   Mori, Akihisa ^a   Jenner, Peter ^b   Kanda, Tomoyuki ^a  

^a KYOWA HAKKO KOGYO CO LTD   (Japan)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Anti parkinsonian; Dyskinesia; L DOPA; MPTP

Indexed keywords

BENSERAZIDE; ISTRADEFYLLINE; LEVODOPA; ADENOSINE A2 RECEPTOR ANTAGONIST; ANTIPARKINSON AGENT; PURINE DERIVATIVE;

ACUTE DRUG ADMINISTRATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CALLITHRIX; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFECT; DRUG MECHANISM; DRUG POTENTIATION; DYSKINESIA; FEMALE; MALE; MOTOR PERFORMANCE; NONHUMAN; PARKINSON DISEASE; TREATMENT DURATION; ANIMAL; MOTOR ACTIVITY; ORAL DRUG ADMINISTRATION; PARKINSONISM; PATHOPHYSIOLOGY;

ADENOSINE A2 RECEPTOR ANTAGONISTS; ADMINISTRATION, ORAL; ANIMALS; ANTIPARKINSON AGENTS; CALLITHRIX; DRUG SYNERGISM; DYSKINESIAS; FEMALE; LEVODOPA; MALE; MOTOR ACTIVITY; PARKINSONIAN DISORDERS; PURINES;

EID: 84899568029     PISSN: 13478613     EISSN: 13478648     Source Type: Journal    
DOI: 10.1254/jphs.13250FP     Document Type: Article

References (26)

1. Fahn S. The history of dopamine and levodopa in the treatment of Parkinson's disease. Mov Disord. 2008;23:S497-S508.
2. Ahlskog JE, Muenter MD. Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord. 2001;16:448-458. (Pubitemid 36041148)
3. Nutt JG. Motor fluctuations and dyskinesia in Parkinson's disease. Parkinsonism Relat Disord. 2001;8:101-108. (Pubitemid 32728023)
4. Marsala SZ, Gioulis M, Ceravolo R, Tinazzi M. A systematic review of catechol-o-methyltransferase inhibitors: efficacy and safety in clinical practice. Clin Neuropharmacol. 2012;35:185-190.
5. Matheson AJ, Spencer CM. Ropinirole: a review of its use in the management of Parkinson's disease. Drugs. 2000;60:115-137. (Pubitemid 30598821)
6. Antonini A, Barone P, Ceravolo R, Fabbrini G, Tinazzi M, Abbruzzese G. Role of pramipexole in the management of Parkinson's disease. CNS Drugs. 2010;24:829-841.
7. 3 expression in rat striatum. J Pharmacol Sci. 2012;120:133-137.
8. Bonuccelli U, Colzi A, Del Dotto P. Pergolide in the treatment of patients with early and advanced Parkinson's disease. Clin Neuropharmacol. 2002;25:1-10. (Pubitemid 34178241)
9. Schiffmann SN, Jacobs O, Vanderhaeghen JJ. Striatal restricted adenosine A2 receptor (RDC8) is expressed by enkephalin but not by substance P neurons: an in situ hybridization histochemistry study. J Neurochem. 1991;57:1062-1067.
10. Obeso JA, Rodriguez-Oroz M, Marin C, Alonso F, Zamarbide I, Lanciego JL, et al. The origin of motor fluctuations in Parkinson's disease: importance of dopaminergic innervation and basal ganglia circuits. Neurology. 2004;62:S17-S30. (Pubitemid 38082849)
11. 2A receptor antagonists KF17837 and KW-6002 potentiate rotation induced by dopaminergic drugs in hemi-Parkinsonian rats. Eur J Pharmacol. 2000;408:249-255.
12. 2A antagonist KW-6002 with L-DOPA or with selective D1 or D2 dopamine agonists increases antiparkinsonian activity but not dyskinesia in MPTP-treated monkeys. Exp Neurol. 2000;162:321-327.
13. 2A receptor antagonist istradefylline (KW-6002) reduces "off" time in Parkinson's disease: a double-blind, randomized, multicenter clinical trial (6002-US-005). Ann Neurol. 2008;63:295-302.
14. Stacy M, Silver D, Mendis T, Sutton J, Mori A, Chaikin P, et al. A 12-week, placebo-controlled study (6002-US-006) of istradefylline in Parkinson disease. Neurology. 2008;70:2233-2240.
15. Mizuno Y, Hasegawa K, Kondo T, Kuno S, Yamamoto M. Japanese Istradefylline Study Group. Clinical efficacy of istradefylline (KW-6002) in Parkinson's disease: a randomized, controlled study. Mov Disord. 2010;25:1437-1443.
16. Hauser RA, Shulman LM, Trugman JM, Roberts JW, Mori A, Ballerini R, et al. Study of istradefylline in patients with Parkinson's disease on levodopa with motor fluctuations. Mov Disord. 2008;23:2177-2185.
17. 2A receptor antagonist istradefylline reduces daily off time in Parkinson's disease. Mov Disord. 2013;28:1138-1141.
18. 2A antagonist: a novel antiparkinsonian agent that does not provoke dyskinesia in parkinsonian monkeys. Ann Neurol. 1998;43:507-513.
19. Tayarani-Binazir KA, Jackson MJ, Rose S, Olanow CW, Jenner P. Pramipexole combined with levodopa improves motor function but reduces dyskinesia in MPTP-treated common marmosets. Mov Disord. 2010;25:377-384.
20. Smith LA, Gordin A, Jenner P, Marsden CD. Entacapone enhances levodopa-induced reversal of motor disability in MPTP-treated common marmosets. Mov Disord. 1997;12:935-945. (Pubitemid 27496771)
21. 2A antagonist prevents dopamine agonist-induced motor complications in animal models of Parkinson's disease. Exp Neurol. 2003;184:285-294.
22. Jenner P. Molecular mechanisms of L-DOPA-induced dyskinesia. Nat Rev Neurosci. 2008;9:665-677.
23. 2A receptors in the brain of Parkinson's disease patients with dyskinesias. Brain. 2004;127: 1075-1084.
24. Tel BC, Zeng BY, Cannizzaro C, Pearce RK, Rose S, Jenner P. Alterations in striatal neuropeptide mRNA produced by repeated administration of L-DOPA, ropinirole or bromocriptine correlate with dyskinesia induction in MPTP-treated common marmosets. Neuroscience. 2002;115:1047-1058. (Pubitemid 35351696)
25. 2A receptor mRNA by dopamine denervation. Eur J Pharmacol. 2002;446:75-82.
26. 2A receptor mRNA in 6-hydroxydopamine-lesioned rats intermittently treated with L-DOPA. Synapse. 2004;52:218-222.